AVE fundamentals

Avecho Biotechnology Ltd. engages in the development and commercialization of human and animal products through its proprietary drug delivery system. It operates through the Production and Human Health segments. The Production segment focuses on manufacturing and sale of TPM and Vital ET for the use in drug delivery and cosmetic formulations. The Human Health segment consists of delivery of pharmaceutical products through gels, injectables and patches including conduct of research and development activities. The company was founded by Mark Gregory Kerr on June 19, 1992 and is headquartered in Clayton, Australia.